REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

Description

This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).

Conditions

Asthma

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).

A Prospective, Real-World, Interventional Study To Evaluate The Effect Of Mepolizumab On Achieving Clinical Remission In Participants With Severe Asthma

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

Condition
Asthma
Intervention / Treatment

-

Contacts and Locations

Little Rock

GSK Investigational Site, Little Rock, Arkansas, United States, 72205

La Jolla

GSK Investigational Site, La Jolla, California, United States, 92037

Newport Beach

GSK Investigational Site, Newport Beach, California, United States, 92663

Aurora

GSK Investigational Site, Aurora, Colorado, United States, 71105

Colorado Springs

GSK Investigational Site, Colorado Springs, Colorado, United States, 80923

New Haven

GSK Investigational Site, New Haven, Connecticut, United States, 06510

Homestead

GSK Investigational Site, Homestead, Florida, United States, 33032

Jacksonville

GSK Investigational Site, Jacksonville, Florida, United States, 32209

Miami

GSK Investigational Site, Miami, Florida, United States, 33125

Tallahassee

GSK Investigational Site, Tallahassee, Florida, United States, 32308

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participant has a confirmed asthma diagnosis and has been prescribed NUCALA by their physician for the treatment of asthma, as per local label. NUCALA can be initiated up to 7 days prior to study enrollment.
  • * No NUCALA use in the 6 months prior to enrollment.
  • * Participants with greater than or equal to (≥)60 percentage (%) predicted forced expiratory volume in 1 second (FEV1) and less than or equal to (≤)4 exacerbations per year, as confirmed by the physician.
  • * Other local prescription criteria of NUCALA not described above at NUCALA initiation (e.g., local reimbursement criteria).
  • * Written informed consent
  • * Investigator concerns about participant's willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare)
  • * Participants currently on maintenance OCS or intramuscular corticosteroids.
  • * Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment
  • * Participants participating in an interventional study with a treatment intervention

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

GlaxoSmithKline,

GSK Clinical Trials, STUDY_DIRECTOR, GlaxoSmithKline

Study Record Dates

2028-06-14